UA92327C2 - Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей - Google Patents

Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей

Info

Publication number
UA92327C2
UA92327C2 UAA200702904A UAA200702904A UA92327C2 UA 92327 C2 UA92327 C2 UA 92327C2 UA A200702904 A UAA200702904 A UA A200702904A UA A200702904 A UAA200702904 A UA A200702904A UA 92327 C2 UA92327 C2 UA 92327C2
Authority
UA
Ukraine
Prior art keywords
compounds
addiction
effective
significant
effects
Prior art date
Application number
UAA200702904A
Other languages
English (en)
Russian (ru)
Inventor
Балвиндер Сингх БХАТТИ
Грегори Дж. Гатто
Йозеф Клюцик
Original Assignee
Таргасепт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Таргасепт, Инк. filed Critical Таргасепт, Инк.
Publication of UA92327C2 publication Critical patent/UA92327C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Описано спосіб лікування лікарської залежності, нікотинової залежності і/або ожиріння, що включає введення N-арилдіазаспіроциклічної сполуки або її фармацевтично прийнятної солі.Сполука ефективна для інгібування продукування й/або секреції допаміну й, отже, ефективна для пригнічення процесу фізіологічної "компенсації", що пов'язаний з усмоктуванням нікотину й/або заборонених лікарських засобів.Сполука може вводитися в ефективних кількостях для інгібування вивільнення допаміну без помітних небажаних побічних ефектів (наприклад, таких побічних ефектів, як значиме збільшення кров'яного тиску й швидкість серцебиття, значимий негативний вплив на травний тракт і значимий негативний вплив на скелетні м'язи).
UAA200702904A 2004-08-20 2005-08-18 Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей UA92327C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60347904P 2004-08-20 2004-08-20

Publications (1)

Publication Number Publication Date
UA92327C2 true UA92327C2 (uk) 2010-10-25

Family

ID=35447974

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200702904A UA92327C2 (uk) 2004-08-20 2005-08-18 Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей

Country Status (16)

Country Link
US (1) US20060058328A1 (uk)
EP (1) EP1784184A2 (uk)
JP (1) JP2008510711A (uk)
KR (1) KR20070043008A (uk)
CN (1) CN101022801A (uk)
AU (1) AU2005277410B2 (uk)
BR (1) BRPI0514509A (uk)
CA (1) CA2575461A1 (uk)
IL (1) IL180929A0 (uk)
MX (1) MX2007002045A (uk)
NO (1) NO20070979L (uk)
NZ (1) NZ552792A (uk)
RU (1) RU2387647C9 (uk)
UA (1) UA92327C2 (uk)
WO (1) WO2006023630A2 (uk)
ZA (1) ZA200701193B (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US8741348B2 (en) 2002-12-20 2014-06-03 Niconovum Ab Physically and chemically stable nicotine-containing particulate material
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
US20110118239A1 (en) * 2008-01-15 2011-05-19 Targacept, Inc. Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane and novel salt forms of the racemate and enantiomers
CN102070640A (zh) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 一种1,7-二氮杂螺[4,5]壬烷及其衍生物的合成方法
ES2623373T3 (es) * 2010-05-27 2017-07-11 Catalyst Biosciences, Inc. Antagonistas no competitivos del receptor nicotínico
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
CN102516146B (zh) * 2011-11-24 2013-10-02 爱斯特（成都）生物制药有限公司 5位为氮的四元氮杂螺环衍生物及其制备方法和用途
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
RU2635105C1 (ru) * 2016-07-15 2017-11-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" Способ получения 4-арил-2,7,9-триазаспиро[4.5]декан-6,8,10-трионов
EA201990424A1 (ru) * 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
KR20230035031A (ko) 2020-06-05 2023-03-10 킨네이트 바이오파마 인크. 섬유아세포 성장 인자 수용체 키나아제의 억제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282947A (en) * 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
EP0842172A1 (en) * 1995-06-29 1998-05-20 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5733912A (en) * 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
DE69900220T2 (de) * 1998-06-12 2002-05-08 Hoffmann La Roche Diaza-spiro[3,5]nonan-Derivate
CA2389034A1 (en) * 1999-10-27 2001-05-03 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
KR20020087134A (ko) * 2000-04-10 2002-11-21 화이자 프로덕츠 인크. 벤조아미드 피페리딘 함유 화합물 및 관련 화합물
NZ551552A (en) * 2002-07-05 2008-03-28 Targacept Inc N-Aryl diazaspirocyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof

Also Published As

Publication number Publication date
IL180929A0 (en) 2007-07-24
CA2575461A1 (en) 2006-03-02
KR20070043008A (ko) 2007-04-24
US20060058328A1 (en) 2006-03-16
RU2007110020A (ru) 2008-09-27
NZ552792A (en) 2009-12-24
WO2006023630A2 (en) 2006-03-02
RU2387647C2 (ru) 2010-04-27
NO20070979L (no) 2007-03-19
RU2387647C9 (ru) 2011-05-27
WO2006023630A3 (en) 2006-05-04
BRPI0514509A (pt) 2008-06-10
JP2008510711A (ja) 2008-04-10
AU2005277410B2 (en) 2010-06-24
ZA200701193B (en) 2009-09-30
AU2005277410A1 (en) 2006-03-02
EP1784184A2 (en) 2007-05-16
MX2007002045A (es) 2007-03-29
CN101022801A (zh) 2007-08-22

Similar Documents

Publication Publication Date Title
UA92327C2 (uk) Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей
NO20050012L (no) N-aryldiazaspiracykliske forbindelser og fremgangsmater for fremstilling og anvendelse derav
HUP0401849A2 (hu) Kinuklidinszármazékok, ezeket tartalmazó gyógyászati készítmények, továbbá ezek alkalmazása M2 és/vagy M3 muszkarin receptor inhibitorként
IL295536B2 (en) Specific tryptamines for use in the treatment of mood disorders
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
MX2009012558A (es) Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
JP2011500506A5 (uk)
MY139107A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments.
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
MXPA06013221A (es) Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros.
JP2019515908A5 (uk)
WO2008087461B1 (en) Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis
MXPA05010020A (es) Derivados de oxamida.
RU2016111390A (ru) Неконкурентные антагонисты никотиновых рецепторов
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
CA2515730A1 (en) Pyrrolidinohydrochinazolines
RU2014128528A (ru) Лечение диабета I и II типа
RU2012114097A (ru) Терапевтический агент против хронической боли
WO2007009012A3 (en) Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
JPS59231057A (ja) カルボン酸アミド化合物およびその誘導体
JP2010536778A5 (uk)
WO2009116774A3 (ko) 혈관 재협착 치료 또는 예방용 조성물